Publications/Patents

  1. Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli A, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C “Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development.” Neuro-Oncology, 2019, 2019 21(4):486-497
  2. Oyer JL, Gitto SB, Altomare DA and Copik AJ “PD-L1 blockade enhances anti-tumor efficacy of NK cells” OncoImmunology (2018) 7(11): e1509819.
  3. Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Phanstiel O 4th, Altomare DA. “Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.” Mol Pharm. (2018) 15(2):369-376
  4. Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, Khaled AR. “Cytokines in immunogenic cell death: Applications for cancer immunotherapy.” Cytokine, (2017) 97:123-132.
  5. Fuse MA, Plati SK, Burns SS, Dinh CT, Bracho O, Yan D, Mittal R, Shen R, Soulakova JN, Copik AJ, Liu XZ, Telischi FF, Chang LS, Franco MC, Fernandez-Valle C. “Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.” Mol Cancer Ther. (2017) 16(11):2387-2398.
  6. Petrilli AM, Garcia J., Bott M, Klingman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ,  Chang LS, Welling DB, Copik AJ,  Fernández-Valle C. “Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.” Oncotarget, (2017) 8(19):31666-31681.
  7. Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh MM, Lee DA, Altomare DA and Copik AJ “NK cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment” Cytotherapy, (2016) 16(5);653-663.
  8. Pandey, V., Oyer, J.L., Igarashi, R.Y., Gitto, S.B., Copik, A.J., Altomare, D.A. “Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.” Oncotarget, (2016) 7(6):7318-28. http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=6939
  9. Solh M, Rathmann K, Chang-Fong S, Lamontagne D, Oyer J, Copik A, Khaled Y. “Method of Mobilization: Implications on Graft Composition and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation” Ann Hematol Oncol. (2016) 3(4):1089.
  10. Doshi M, Copik A, Gesquiere AJ. “Development and characterization of conducting polymer nanoparticles for photodynamic therapy in vitro” Photodiagnosis Photodyn Ther. (2015) 12(3):476-89. doi: 10.1016/j.pdpdt.2015.04.010.
  11. Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, Khaled YA, Altomare DA and Copik AJ “Generation of highly cytotoxic Natural Killer cells for treatment of AML using feeder-free, particle based approach” Biology of Blood and Marrow Transplantation (2015) 21(4):632-9. doi: 10.1016/j.bbmt.2014.12.037.
  12. Doshi M, Krienke M, Khederzadeh S, Sanchez H, Copik A, Oyer J. Gesquiere AJ. “Conducting Polymer Nanoparticles for Targeted Cancer Therapy” RSC Advances (2015) 5: 37943-37956, doi:10.1039/C5RA05125H.
  13. Copik AJ, Baldys A, Nguyen K, Sahdeo S, Ho H, Kosaka A, Dietrich PJ, Fitch B, Raymond JR, Ford APD, Button D and Milla ME “Isoproterenol acts as a biased agonist of the Alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway” PloS One (2015) 21;10(1):e0115701. doi: 10.1371/journal.pone.0115701.
  14. Lee MW, Bassiouni R, Sparrow NA, Iketani A, Boohaker RJ, Moskowitz C, Vishnubhotla P, Khaled AS, Oyer J, Copik A, Fernandez-Valle C, Perez JM, Khaled AR. “The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption.” Cell Death Dis. (2014) 5(5):e1249.
  15. Doshi M, Treglown K, Copik A, Gesquiere AJ. “Composite Conjugated Polymer/Fullerene Nanoparticles as Sensitizers in Photodynamic Therapy for Cancer.” BioNanoScience (2013) 3(4):15-26.
  16. Peng P, Wang C, Shi Z, Johns VK, Ma L, Oyer J, Copik A, Igarashi R, Liao Y. “Visible-light activatable organic CO-releasing molecules (PhotoCORMs) that simultaneously generate fluorophores. Organic and Biomolecular Chemistry (2013) 11(39):6671-4.
  17. Petrilli A, Copik AJ, Posadas M, Chang L-S, Welling B, Giovannini M, Fernández-Valle C. “LIM Domain Kinases as Potential Therapeutic Targets for Neurofibromatosis Type 2” Oncogene (2013) 33(27):3571-82.
  18. Copik AJ, Ma C, Kosaka A, Sahdeo S, Trane A, Ho H, Dietrich PS, Ford APD, Button D, Milla ME. “Facilitatory interplay in a1A and b2 adrenoceptor function reveals a non-Gq signaling mode: implications for diversification of intracellular signal transduction” Molecular Pharmacology (2009) 75(3), 713-728.

Complete List of Published Work in My Bibliography:

http://www.ncbi.nlm.nih.gov/sites/myncbi/1Lqio6wYorqko/bibliography/47552156/public/?sort=date&direction=descending

PATENTS:

Copik AJ, Oyer J, Reddy V “IN VIVO GENERATION OF CYTOTOXIC NATURAL KILLER CELLS AND ASSOCIATED CANCER TREATMENT METHODS” Patent no. US 9,623,082

Copik AJ, Oyer J, Igarashi RY, Altomare D. “Methods and compositions high scale therapeutic production of memory NK cells” Patent no. US 10,300,089 B2